Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Opioids: no effect without side effect

21.01.2019

Through genetic changes to the opioid receptor in mice, pharmacologists at Jena University Hospital have succeeded in almost completely suppressing the development of opioid tolerance. The pain-relieving effect actually improved and continued even when the drug was administered for longer periods. However, adverse effects such as respiratory depression and constipation, as well as withdrawal symptoms, were unchanged. The study, now published in Nature Communications, suggests that the development of opioid tolerance is mediated by phosphorylation and desensitisation of the opioid receptor. These findings can be used in developing improved opioids.

More than two-thirds of the over 70,000 drug-related deaths in the USA in 2017 were due to opioid overdoses. The rapidly increasing abuse of the strong painkillers over the past 20 years is even referred to as the opioid crisis and it led US President Donald Trump to declare a state of emergency in public health care in 2017. In almost all cases, the opioid victims died as a result of respiratory paralysis.


Pharmacologist Dr Andrea Kliewer of Jena University Hospital has clarified essential mechanisms for the development of tolerance to opioids such as fentanyl and morphine.

Photo: Michael Szabó/UKJ

Shallower breathing and a tendency to constipation are frequent side effects of the highly effective drugs, which are used for the treatment of severe pain, for example after operations or in the case of cancer.

In addition, there is a great potential for addiction, which was shamefully underestimated, especially in the case of synthetic opioids that were launched on the market a good 20 years ago. The risk of side effects is further increased by a habituation effect that occurs with repeated administration of opioids: ever higher doses must be given to achieve the same pain relief.

While this tolerance development reduces the pain-relieving effect, the side effects remain almost the same. Researchers and pharmaceutical companies are working relentlessly to find new substances that activate the opioid receptor and effectively relieve pain even after prolonged administration, but do not cause any dangerous side effects.

However, the molecular regulation mechanisms of opioid receptors, which are the specific docking sites for opioids on the surface of nerve cells, are far from being understood in detail.

“In principle, we differentiate between two major signalling pathways at the opioid receptor: G proteins mediate the pain-relieving effect, while the binding of phosphate groups and the scaffold protein arrestin to the receptor mediates the desensitisation effect,” explains Professor Stefan Schulz of Jena University Hospital.

In its search for the mechanism that gradually weakens the effect of the fundamentally effective painkiller, the group led by Stefan Schulz has long had its sights on the desensitisation of receptors, a kind of protective mechanism of the cell against over-stimulation, which makes it less sensitive to excessive stimulation.

As part of Transregio ‘ReceptorLight’, funded by the German Research Foundation (DFG), the Jena scientists, together with colleagues from Sydney, London und Gainesville, Florida, have now been able to confirm their assumption in a study using genetically modified mice.

They altered the receptor in the animals in such a way that it no longer had binding sites for the phosphate groups. Desensitisation could no longer take place at the altered receptors and the receptors were no longer degraded in the nerve cell but remained in the cell membrane.

The researchers then tested the effect of the natural agent morphine and the highly effective synthetic substance fentanyl on the genetically modified mice. “Compared to wild type mice, a single administration of a much lower dose was sufficient to achieve the same pain relief – almost 60 per cent for fentanyl and less than half for morphine. This effect also lasted longer,” says the lead author of the study, Dr Andrea Kliewer.

To test the habituation effect, the animals were given the painkiller continuously for seven days. Compared with the first day, a fentanyl dose thirteen times higher than the initial dose was necessary to achieve the same pain-relieving effect in the wild type animals.

For the other mice, significantly less than double the initial dose was sufficient. Andrea Kliewer: “The animals with opioid receptors without phosphorylation sites developed virtually no habituation to the active substances. This confirms our assumption that tolerance and desensitisation occur via the same molecular mechanisms.”

The researchers carefully examined the test animals for side effects such as respiratory depression and constipation, as well as dependence and withdrawal symptoms. To this end, they recorded lung function and the faeces amounts; in behavioural tests, they observed the animals for signs of addiction and administered the opioid antagonist naloxone to simulate withdrawal.

The surprising result: all the adverse effects were still present and respiratory depression was even more pronounced in the genetically modified animals than in the wild type mice. It was shown that when the opioid dose is varied, pain reduction and side effects change to the same extent in all animals. “Our results clearly indicate that the arrestin signalling pathway of the opioid receptor only regulates desensitisation and tolerance development, but that the side effects and dependency, as well as the desired analgesia, are mediated by the G proteins. This has great significance for the further development of opioid-based painkillers,” notes Stefan Schulz.

Wissenschaftliche Ansprechpartner:

Prof. Stefan Schulz, Dr Andrea Kliewer
Institute of Pharmacology and Toxicology, Jena University Hospital
Tel.: +49 (0)3641/9395651, 9395667
E-mail: stefan.schulz@med.uni-jena.de, andrea.kliewer@med.uni-jena.de

Originalpublikation:

Kliewer A, et al. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat. Comm. 2019, DOI: 10.1038/s41467-018-08162-1

Dr. Uta von der Gönna | idw - Informationsdienst Wissenschaft

Further reports about: Opioids morphine opioid receptor pain pain relief receptor respiratory depression

More articles from Health and Medicine:

nachricht Underwater Snail-o-Bot gets kick from light
27.02.2020 | Max-Planck-Institut für Intelligente Systeme

nachricht Existing drugs may offer a first-line treatment for coronavirus outbreak
27.02.2020 | Norwegian University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: High-pressure scientists in Bayreuth discover promising material for information technology

Researchers at the University of Bayreuth have discovered an unusual material: When cooled down to two degrees Celsius, its crystal structure and electronic properties change abruptly and significantly. In this new state, the distances between iron atoms can be tailored with the help of light beams. This opens up intriguing possibilities for application in the field of information technology. The scientists have presented their discovery in the journal "Angewandte Chemie - International Edition". The new findings are the result of close cooperation with partnering facilities in Augsburg, Dresden, Hamburg, and Moscow.

The material is an unusual form of iron oxide with the formula Fe₅O₆. The researchers produced it at a pressure of 15 gigapascals in a high-pressure laboratory...

Im Focus: From China to the South Pole: Joining forces to solve the neutrino mass puzzle

Study by Mainz physicists indicates that the next generation of neutrino experiments may well find the answer to one of the most pressing issues in neutrino physics

Among the most exciting challenges in modern physics is the identification of the neutrino mass ordering. Physicists from the Cluster of Excellence PRISMA+ at...

Im Focus: Therapies without drugs

Fraunhofer researchers are investigating the potential of microimplants to stimulate nerve cells and treat chronic conditions like asthma, diabetes, or Parkinson’s disease. Find out what makes this form of treatment so appealing and which challenges the researchers still have to master.

A study by the Robert Koch Institute has found that one in four women will suffer from weak bladders at some point in their lives. Treatments of this condition...

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

New molten metal hybrid filters from TU Freiberg will make components even safer and more resistant in the future

28.02.2020 | Materials Sciences

Polymers get caught up in love-hate chemistry of oil and water

28.02.2020 | Life Sciences

Two NE tree species can be used in new sustainable building material

28.02.2020 | Architecture and Construction

VideoLinks
Science & Research
Overview of more VideoLinks >>>